Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck bravecto — Worldwide reported growth YoY (%) (%)
Form 10-Q / 10-K Animal Health MD&A
Latest, Q2 2026
7.0%
Period ended Jun 30, 2026
Change on a year earlier
+6.0 pts
1.0% in Q2 2025
History
5 quarters
Since Q3 2023
Sources
5
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Bravecto — Worldwide reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 7.0% | +6.0 pts | Form 10-Q (mrk-20260630.htm, filed 2026-08-07) ↗ |
| Q1 2026 | Mar 31, 2026 | 16.0% | – | Form 10-Q (mrk-20260331.htm, filed 2026-05-04) ↗ |
| Q3 2025 | Sep 30, 2025 | -1.0% | – | Form 10-Q (mrk-20250930.htm, filed 2025-11-05) ↗ |
| Q2 2025 | Jun 30, 2025 | 1.0% | – | Form 10-Q (mrk-20250630.htm, filed 2025-08-05) ↗ |
| Q3 2023 | Sep 30, 2023 | -3.0% | – | Form 10-Q (mrk-20230930.htm, filed 2023-11-03) ↗ |
Cite this data
StockData. (2026). Merck Bravecto — Worldwide reported growth YoY (%) (%), quarterly Q3 2023–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_bravecto_nom_yoy
See every metric in the Merck KPI table. Data updated Oct 26, 2026.